Last month, the U.S. House of Representatives passed H.R. 160 to repeal the 2.3% medical device excise tax passed as a part of the healthcare reform platform enacted by the Obama administration. The U.S. medical device industry is hopeful that reform of this tax might remove the inherent limits on R&D spending that were a natural evolution of the initial tax that was passed.
The effect of t...
Read More
Read More